↠Research library / Growth hormone axis
Sermorelin is a synthetic fragment of your body's own growth hormone-releasing hormone, specifically the first 29 amino acids, which is the portion that carries the functional activity. It's the signal, not the hormone.
That distinction matters more than most explanations let on. Injecting growth hormone directly overrides your body's regulatory system: you get a sustained, non-physiological level and your pituitary reduces its own output in response. Sermorelin instead prompts your pituitary to release GH through its normal pulsatile pattern, which preserves the feedback loops, including the ones that stop release when levels are already adequate.
The practical consequence is a lower ceiling on effect and a different safety profile. That's a genuine trade-off, not purely an advantage, and anyone presenting it as strictly better is simplifying.
After subcutaneous administration, peak plasma concentration is reached in roughly 5-20 minutes, with a half-life of about 11-12 minutes whether given intravenously or subcutaneously.[2]
That very short half-life is why it's typically administered at night. Endogenous GH release is pulsatile and predominantly nocturnal, tightly coupled to slow-wave sleep. Dosing before sleep aligns the signal with the window where your body was going to release GH anyway.
It also means your sleep quality is a direct input into whether this works. If you're sleeping five broken hours, you're asking the drug to amplify a pulse that's already suppressed.
Sermorelin was FDA-approved in 1997 for idiopathic growth hormone deficiency in children with growth failure. Six months of treatment produced significant increases in GH release and growth velocity in GH-deficient children.[1] It was later withdrawn from the US market for commercial reasons, not safety findings, a distinction worth knowing, because it's frequently misrepresented in both directions.
In adults, the relevant evidence comes from GHRH-analog trials:
Sermorelin is well-tolerated and has an established role as a diagnostic agent for growth hormone deficiency.[3]
Nearly all of the adult data is in older adults with measurable age-related decline. Evidence for clinical benefit in healthy, younger adults with intact GH axes is limited. The mechanism is plausible and the biomarker changes are real, but a rise in IGF-1 is not itself an outcome, and anyone presenting biomarker movement as proof of a body composition result is skipping a step.
Thyroid hormone, corticosteroids and glucose-affecting medications all interact with this axis, which is why clinical studies of it control for them.
Generally well tolerated. Most common are injection site reactions, redness, swelling, pain. Less common: flushing, headache, dizziness, nausea, altered taste. Less common still: fluid retention, joint discomfort, and effects on insulin sensitivity, which is why glucose monitoring matters in anyone with metabolic disease.
Adverse events involving regulated products can be reported to FDA MedWatch at 1-800-FDA-1088.
Subcutaneous injection, typically at night on an empty stomach, because food, particularly fat and carbohydrate near dosing, blunts GH release.
We don't publish dosing. Your dose is determined by your prescribing provider based on your history, labs, age, and goals. A dosing chart on a public page aimed at strangers is exactly what makes this category dangerous.
Sermorelin acetate is available through compounding pharmacies with a valid prescription. It is not currently marketed as an FDA-approved finished product in the US. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality.
Of the compounds most commonly discussed in this category, sermorelin has one of the clearer regulatory pathways, which is a large part of why it's a foundation of legitimate practice while several better-marketed compounds are not currently available at all.
No, and the difference is fundamental. HGH is the hormone. Sermorelin is a signal that asks your pituitary to release its own. Different effect sizes, different regulatory status, different safety profiles. Note also that HGH distribution outside approved indications carries its own federal criminal statute, they are not interchangeable in any sense.
Half-life is 11-12 minutes and natural GH release is predominantly nocturnal and tied to slow-wave sleep. Night dosing aligns the signal with the body's own pulse.
IGF-1 is the standard marker used to track response in the published studies, with a baseline measured before the study period begins.
Sleep quality changes are typically reported first, often within two to three weeks. Recovery follows. Body composition is a 16-26 week question based on the trial literature.
Written and published by third parties. Not affiliated with or endorsed by us, and we don't control their content. Provided for general education.
Tesamorelin · Full library · · Safety & sourcing